Switching addictions between HER2 and FGFR2 in HER2-positive breast tumor cells: FGFR2 as a potential target for salvage after lapatinib failure

This publication has 14 references indexed in Scilit:

• Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
  International Journal of Cancer, 2010
• Fibroblast growth factor signalling: from development to cancer
  Nature Reviews Cancer, 2010
• Loss of HER2 Amplification Following Trastuzumab-Based Neoadjuvant Systemic Therapy and Survival Outcomes
  Clinical Cancer Research, 2009
• Systems Biology Reveals New Strategies for Personalizing Cancer Medicine and Confirms the Role of PTEN in Resistance to Trastuzumab
  Cancer Research, 2009
• Phosphatidylinositol 3-Kinase Hyperactivation Results in Lapatinib Resistance that Is Reversed by the mTOR/Phosphatidylinositol 3-Kinase Inhibitor NVP-BEZ235
  Cancer Research, 2008
• Drug-sensitiveFGFR2mutations in endometrial carcinoma
  Proceedings of the National Academy of Sciences, 2008
• Common variants on chromosome 5p12 confer susceptibility to estrogen receptor–positive breast cancer
  Nature Genetics, 2008
• Expression of p95HER2, a Truncated Form of the HER2 Receptor, and Response to Anti-HER2 Therapies in Breast Cancer
  JNCI: Journal of the National Cancer Institute, 2007
• Relationship of Epidermal Growth Factor Receptor Expression to ErbB-2 Signaling Activity and Prognosis in Breast Cancer Patients
  Journal of Clinical Oncology, 2005
• Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/neuOncogene
  Science, 1987